# A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors

> **NCT04836663** · PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer

## Interventions

- **DRUG:** TQ-B3525 tablet

## Key facts

- **NCT ID:** NCT04836663
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-23
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2021-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04836663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04836663, "A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04836663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*